Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology
- 1 June 1982
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 8 (2) , 151-156
- https://doi.org/10.1007/bf00255475
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routesCancer Chemotherapy and Pharmacology, 1980
- High-Dose Medroxyprogesterone Acetate (MPA) Treatment in Advanced Breast Cancer. A ReviewTumori Journal, 1979
- High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapyCancer Chemotherapy and Pharmacology, 1979
- Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinomaActa Obstetricia et Gynecologica Scandinavica, 1979
- A radioimmunoassay for serum medroxyprogesterone acetateThe Journal of Steroid Biochemistry and Molecular Biology, 1978
- High Dose Medroxyprogesterone Acetate (MPA) Treatment in Metastatic Carcinoma of the Breast: A Dose-Response EvaluationTumori Journal, 1978
- Hormonoprophylaxis and hormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetateGynecologic Oncology, 1978
- High Dose Medroxyprogesterone-Acetate Treatment in Advanced Mammary Carcinoma: A Phase II InvestigationActa Radiologica: Oncology, Radiation, Physics, Biology, 1978
- Serum Medroxyprogesterone Acetate (MPA) Concentrations and Ovarian Function Following Intramuscular Injection of Depo-MPAJournal of Clinical Endocrinology & Metabolism, 1977
- Measurement of Medroxyprogesterone Acetate (Provera) by Radioimmunoassay1Journal of Clinical Endocrinology & Metabolism, 1971